190 related articles for article (PubMed ID: 35098169)
1. Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy.
Kool R; Marcq G; Shinde-Jadhav S; Mansure JJ; Saleh R; Rajan R; Aprikian A; Tanguay S; Cury FL; Brimo F; Souhami L; Kassouf W
Eur Urol Open Sci; 2022 Feb; 36():26-33. PubMed ID: 35098169
[TBL] [Abstract][Full Text] [Related]
2. Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans.
Kumar A; Cherry DR; Courtney PT; Nalawade V; Kotha N; Riviere PJ; Efstathiou J; McKay RR; Karim Kader A; Rose BS; Stewart TF
Eur Urol Open Sci; 2021 Aug; 30():1-10. PubMed ID: 34337540
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?
Hurmuz P; Ozyigit G; Kilickap S; Esen CSB; Akdogan B; Ozen H; Akyol F
Urol Oncol; 2021 Jun; 39(6):368.e19-368.e29. PubMed ID: 33189528
[TBL] [Abstract][Full Text] [Related]
4. Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers.
Kool R; Marcq G; Breau RH; Black PC; Shayegan B; Kim M; Busca I; Abdi H; Dawidek MT; Uy M; Fervaha G; Cury FL; Alimohamed NS; Izawa JI; Jeldres C; Rendon R; Siemens DR; Kulkarni GS; Kassouf W
Eur Urol Oncol; 2023 Dec; 6(6):597-603. PubMed ID: 37005214
[TBL] [Abstract][Full Text] [Related]
5. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
6. Prognostic values of preoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and lymphocyte- to-monocyte ratio for patients with muscle- invasive bladder cancer undergoing radical cystectomy.
Lei Y; Jiao D; Yao Z; Wang L; Zhao Z
Arch Esp Urol; 2022 Apr; 75(3):287-294. PubMed ID: 35435163
[TBL] [Abstract][Full Text] [Related]
7. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
8. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
9. Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer.
Almarzouq A; Kool R; Al Bulushi Y; Marcq G; Souhami L; Cury FL; Brimo F; Chong J; Kassouf W
Urol Oncol; 2022 May; 40(5):194.e15-194.e22. PubMed ID: 34862117
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment PLR Is Preferable to NLR and LMR as a Predictor in Locally Advanced and Metastatic Bladder Cancer.
Karan C; Yaren A; Demirel BC; Dogan T; Ozdemir M; Demiray AG; Taskoylu BY; Degirmencioglu S; Dogu G; Ozhan N; Cakiroglu U; Celikyurek A
Cancer Diagn Progn; 2023; 3(6):706-715. PubMed ID: 37927800
[TBL] [Abstract][Full Text] [Related]
11. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
Oncotarget; 2017 Feb; 8(8):12891-12901. PubMed ID: 28039452
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
[TBL] [Abstract][Full Text] [Related]
13. Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.
Buisan O; Orsola A; Areal J; Font A; Oliveira M; Martinez R; Ibarz L
Clin Genitourin Cancer; 2017 Feb; 15(1):145-151.e2. PubMed ID: 27364982
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.
Black AJ; Zargar H; Zargar-Shoshtari K; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Griffin J; Montgomery JS; Vasdev N; Yu EY; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Daneshmand S; Sridhar SS; Black PC
Urol Oncol; 2020 Jan; 38(1):3.e17-3.e27. PubMed ID: 31676278
[TBL] [Abstract][Full Text] [Related]
15. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.
Cantiello F; Russo GI; Vartolomei MD; Farhan ARA; Terracciano D; Musi G; Lucarelli G; Di Stasi SM; Hurle R; Serretta V; Busetto GM; Scafuro C; Perdonà S; Borghesi M; Schiavina R; Cioffi A; De Berardinis E; Almeida GL; Bove P; Lima E; Ucciero G; Matei DV; Crisan N; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Mirone V; Shariat SF; Ferro M
Eur Urol Oncol; 2018 Oct; 1(5):403-410. PubMed ID: 31158079
[TBL] [Abstract][Full Text] [Related]
16. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy.
Zhang GM; Zhu Y; Luo L; Wan FN; Zhu YP; Sun LJ; Ye DW
Tumour Biol; 2015 Nov; 36(11):8537-43. PubMed ID: 26032095
[TBL] [Abstract][Full Text] [Related]
17. Conditional survival of trimodal therapy for nonmetastatic muscle-invasive bladder cancer: A SEER database analysis.
Shangguan W; Hu J; Xie Y; Chen Z; Zhong Q; Zheng Z; Zhu D; Zhang Y; Yang J; Han J; Xie W
Cancer Med; 2022 Jun; 11(12):2356-2365. PubMed ID: 35301806
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
[No Abstract] [Full Text] [Related]
19. Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival with Bladder Cancer after Radical Cystectomy: a retrospective study.
Peng D; Gong YQ; Hao H; He ZS; Li XS; Zhang CJ; Zhou LQ
BMC Cancer; 2017 Jun; 17(1):391. PubMed ID: 28578683
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma.
Lee SM; Russell A; Hellawell G
Korean J Urol; 2015 Nov; 56(11):749-55. PubMed ID: 26568792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
